FindTrial
Sign In

A Phase I, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of MEDI-575 in Patients With Advanced Solid Malignancies

A Phase I, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of MEDI-575 in Patients With Advanced Solid Malignancies

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221095
Enrollment
Unknown
Registered
2010-05-12
Start date
2010-05-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Malignancies

Interventions

investigational material(s) Generic name etc : MEDI-575 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Sponsors

AstraZeneca
Lead Sponsor
MedImmune LLC
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Having advanced solid malignancy for which no curative or standard therapies exist - Karnofsky performance status of 60 or more - Patients must have histological confirmed diagnosis of HCC with no standard therapy available (for only expansion part)

Exclusion criteria

Exclusion criteria: - Inadequate bone marrow reserve or organ function - Major surgery within 4 weeks or minor surgery within 2 weeks prior to receipt of MEDI-575. Patients must have no unhealed wounds or unhealed fractures - History of allergy or reaction to any component of the MEDI-575 and/or monoclonal antibody

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026